Sponsor:Amylin Pharmaceuticals, a wholly owned subsidiary of AstraZeneca
EXSCEL evaluated the cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes.
Randomised, placebo-controlled global clinical trial performed in people with type 2 diabetes diabetes, with or without previous cardiovascular disease. In total, 14,752 patients were enrolled between 18th June 2010 and 16th September 2015. EXSCEL was coordinated jointly by the DTU and the Duke Clinical Research Institute (DCRI) and conducted in 687 sites from 35 countries.
The results of EXSCEL were reported at the 2017 meeting of the EASD. It met its primary safety endpoint of non-inferiority for the primary composite cardiovascular endpoint (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke). The corresponding efficacy endpoint analysed for superiority did not reach statistical significance, although a pre-specified analysis suggested all-cause mortality was lower with exenatide compared to placebo. The primary results paper is available here.
The Exenatide Study of Cardiovascular Event Lowering (EXSCEL) is a trial that assessed the long-term cardiovascular safety and efficacy of once-weekly exenatide, administered in patients with type 2 diabetes who had a wide range of cardiovascular risk. In this video, Professor Rury Holman shares his insights into the trial results.[Watch video]
The ACP Journal Club has identified EXCSEL as an original study that warrants immediate attention by physicians attempting to keep pace with important advances in internal medicine.[Click here to see review]
On Wednesday December 6th, Professor Angelyn Bethel presented new data from the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). The invited talk, presented within the "Latest Cardiovascular Clinical Trials" symposium, shared a new meta-analysis of the four glucagon-like peptide-1 receptor agonist cardiovascular outcome trials conducted to date....[Read more...]